GLPBio

Cyclo (-RGDfK)

Catalog No.: GC17610Purity:>98.00%Synonyms: Cyclo(-Arg-Gly-Asp-D-Phe-Lys)
Cyclo (-RGDfK) is a highly efficient and highly specific αvβ3 integrin inhibitor, with an IC₅₀ of only 0.94nM. Cyclo(-RGDfK) can precisely target the αvβ3 integrin on the surface of tumor cells.

Products are for research use only. Not for human use. We do not sell to patients.


Cyclo (-RGDfK)
Cas No.: 161552-03-0
1mgIn Stock
$37.00
1
5mgIn Stock
$81.00
1
10mgIn Stock
$126.00
1
25mgIn Stock
$214.00
1
50mgIn Stock
$301.00
1
100mgIn Stock
$420.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Cyclo (-RGDfK) is a highly efficient and highly specific αvβ3 integrin inhibitor, with an IC₅₀ of only 0.94nM. Cyclo(-RGDfK) can precisely target the αvβ3 integrin on the surface of tumor cells[1]. Thereby Cyclo(-RGDfK) is therefore widely used in studies targeting tumor neovasculature and cancer cells [2]. Cyclo(-RGDfK) can inhibit cancer cell proliferation and migration[3]. Moreover, Cyclo(-RGDfK) is frequently employed as a core ligand for constructing αvβ3-targeted imaging probes or drug delivery systems in tumor imaging studies[4].

In vitro, pretreatment of HepG2 and A549 cells with Cyclo(-RGDfK) (1–10μM) for 4–6h significantly enhanced cellular uptake of the cRGD-PEG-g-(PBYP-ss-CPT) nanoprodrug; compared to the non-cRGD control group, intracellular drug accumulation increased and cell viability was significantly reduced[5]. Pretreatment of A7R5 cells with Cyclo(-RGDfK) (20nM) for 1h followed by 12h stimulation with FPA (10⁻²μM) significantly inhibited cell migration and proliferation, downregulated integrin αVβ3/PI3K/AKT pathway-related protein expression, and reduced Cyclin D1 and PCNA levels[6].

In vivo, intranasal administration of Cyclo(-RGDfK) (2.0μg) 1h prior to modeling significantly inhibited integrin αVβ3/MAPKs/MMP-9 pathway activation, alleviated blood–brain barrier disruption, and improved neurological deficits in a rat model of subarachnoid hemorrhage (SAH)[7]. Cyclo(-RGDfK)-conjugated gold nanoshells (400mg/kg) were injected intravenously into HCT116 colon cancer-bearing nude mice; 24h later, near-infrared laser thermotherapy (47°C × 10min) significantly enhanced tumor vascular-targeted thermal ablation, resulting in more extensive necrosis and vascular disruption[8].

References:
[1] Simeček J, Notni J, Kapp TG, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
[2] Jin ZH, Furukawa T, Degardin M, et al. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4. Mol Cancer Ther. 2016 Sep;15(9):2076-85.
[3] Kalaydina RV, Zhou H, Markvicheva E, et al. Impact of Fucosylation on Self-Assembly of Prostate and Breast Tumor Spheroids by Using Cyclo-RGDfK(TPP) Peptide and Image Object Detection. Onco Targets Ther. 2019 Dec 17;12:11153-11173.
[4] Yoshimoto M, Hayakawa T, Mutoh M, et al. In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. J Nucl Med. 2012 May;53(5):765-71.
[5] Zhou R, Zhang M, He J, et al. Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells. ACS Omega. 2022 Jun 7;7(24):21325-21336.
[6] Fang R, Yang Q, Wu D, et al. Fibrinopeptide a promotes the proliferation and migration of vascular smooth muscle cells by regulating the integrin αVβ3/PI3K/AKT signaling pathway. Mol Biol Rep. 2025 Feb 5;52(1):205.
[7] Okada T, Suzuki H, Travis ZD, et al. SPARC Aggravates Blood-Brain Barrier Disruption via Integrin αVβ3/MAPKs/MMP-9 Signaling Pathway after Subarachnoid Hemorrhage. Oxid Med Cell Longev. 2021 Nov 11;2021:9739977.
[8] Xie H, Diagaradjane P, Deorukhkar AA, et al. Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine. 2011;6:259-69.

Protocol

Cell experiment [1]:

Cell lines

Rat thoracic artery smooth muscle cells (A7R5)

Preparation Method

A7R5 cells were seeded in 6-well plates at 80% confluence, serum-starved overnight, and then treated with Fibrinopeptide A (FPA, 10⁻²µM) for 12h to establish the pro-atherogenic stimulation model. Cells were divided into three groups: control (serum-free DMEM), FPA group, and Cyclo(-RGDfK) (20nM) pre-treatment followed by FPA group.

Reaction Conditions

20nM; 1h pre-incubation at 37 °C followed by 12h FPA (10⁻²µM) exposure

Applications

Cyclo(-RGDfK) significantly inhibited FPA-induced A7R5 migration and proliferation by blocking integrin αVβ3, thereby down-regulating PI3K/AKT signaling and decreasing Cyclin D1 and PCNA expression.
Animal experiment [2]:

Animal models

Sprague-Dawley rats

Preparation Method

SAH was induced by endovascular perforation. 1 h before modeling, rats received intranasal administration of 2.0μg cyclo(-RGDfK) dissolved in 4μL PBS; recombinant SPARC (0.3μg) was given intracerebroventricularly 1h after SAH. Neurological scores, brain water content, IgG extravasation, and Western blot analyses were performed 24h post-SAH.

Dosage form

2.0μg; IN

Applications

Cyclo(-RGDfK) significantly ameliorated post-SAH blood–brain barrier disruption and neurological deficits by inhibiting integrin αVβ3/MAPKs/MMP-9 signaling.

References:
[1] Fang R, Yang Q, Wu D, et al. Fibrinopeptide a promotes the proliferation and migration of vascular smooth muscle cells by regulating the integrin ?V?3/PI3K/AKT signaling pathway. Mol Biol Rep. 2025 Feb 5;52(1):205.
[2] Okada T, Suzuki H, Travis ZD, et al. SPARC Aggravates Blood-Brain Barrier Disruption via Integrin ?V?3/MAPKs/MMP-9 Signaling Pathway after Subarachnoid Hemorrhage. Oxid Med Cell Longev. 2021 Nov 11;2021:9739977.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
161552-03-0
Synonyms
Cyclo(-Arg-Gly-Asp-D-Phe-Lys)
Chemical Name
2-[(2S,5R,8S,11S)-8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
SMILES
C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O
Molecular Formula
C27H41N9O7
Molecular Weight
603.7
Solubility
≥ 30.185mg/mL in DMSO, ≥ 59.2 mg/mL in Water
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Cyclo (-RGDfK)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%